Skip to main content

Advertisement

Table 2 Factors associated with rituximab response in cohorts 1 and 2

From: Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis

  Characteristic EULAR non-responders EULAR responders Univariate p value Multivariate p value
OR (95% CI) OR (95% CI)
Cohort 1 (n = 111) DAS28-CRP 3.2–5.1 (Ref) 12 (46.2%) 14 (53.8%) 4.0 (1.55–10.36) 0.004 5.24 (1.85–14.85) 0.002
>5.1 15 (17.6%) 70 (82.4%)
RF or anti-CCP Negative (Ref) 7 (41.2%) 10 (58.8%) 2.59 (0.88–7.67) 0.08 3.48 (1.04–11.60) 0.04
Positive 20 (21.3%) 74 (78.7%)
IgG > ULN (g/L) No (Ref) 21 (30.9%) 47 (69.1%) 2.76 (1.01–7.52) 0.048 2.82 (0.97–8.14) 0.056
Yes 6 (14.0%) 37 (86.0%)
Detectable IL-33 No (Ref) 23 (27.4%) 61 (72.6%) 2.17 (0.62–6.95) 0.19
Yes 4 (14.8%) 23 (85.2%)
Cohort 2 (n = 74) Disease activity DAS28-CRP 3.2–5.1 (Ref) 14 (36.8%) 24 (63.2%) 2.92 (0.97–8.73) 0.056
>5.1 6 (16.7%) 30 (83.3%)
RF or anti-CCP Negative (Ref) 2 (100%) 0 (0%) 14.72 (0.34–629.71) 0.16 32.76 (0.7–999) 0.076
Positive 18 (25.0%) 54 (75%)
IgG > ULN (g/L) No (Ref) 15 (37.5%) 25 (62.5%) 2.10 (0.58–7.57) 0.26
Yes 4 (22.2%) 14 (77.8%)
Detectable IL-33 No (Ref) 14 (35.9%) 25 (64.1%) 2.71 (0.91–8.10) 0.07 3.73 (1.12–12.38) 0.03
Yes 6 (17.1%) 29 (82.9%)
  1. Values are given as n (%) of responders or non-responders with a given characteristic
  2. Rituximab response was evaluated at week 24 according to EULAR response
  3. anti-CCP anti-cyclic citrullinated peptide antibody, CI confidence interval, DAS28-CRP Disease Activity Score in 28 joints by C-reactive peptide, EULAR European League Against Rheumatism, Ig immunoglobulin, OR odds ratio, Ref referent, RF rheumatoid factor, ULN upper limit of normal (i.e., 12.7 g/L)